Severe burn biotech MediWound files for a $86 million IPO

By Renaissance Capital,

Shutterstock photo

MediWound, a biotech developing treatments for severe burns and other hard-to-heal wounds, filed on Monday with the SEC to raise up to $86 million in an initial public offering. The Yavne, Israel-based company, which was founded in 2000, plans to list on the NASDAQ under the symbol MDWD. MediWound initially filed confidentially on December 23, 2013. Credit Suisse, Jefferies, and BMO Capital Markets are the joint bookrunners on the deal. No pricing terms were disclosed.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

This article appears in: News Headlines IPOs
Referenced Stocks:

More from Renaissance Capital


Renaissance Capital

Renaissance Capital

Follow on:

Find a Credit Card

Select a credit card product by:
Select an offer:
Data Provided by